Pharma News, 2024

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved TMC Pharma’s Nulibry (fosdenopterin) to treat patients with the rare genetic disease molybdenum cofactor d...

LDL-C is a causal risk factor for ASCVD and increases the risk of heart disease and stroke. Novartis has shared new real-world data for its Leqvio (inclisiran) in reducing low-density lipoprot...

AdrenoMed AG, the vascular integrity company, today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to its lead product candidate enibarcimab, a fir...

Pfizer intends to submit data from MONeT to regulatory agencies in a bid to expand the vaccine’s indicated treatment population.

Eurofins Scientific has purchased the largest independent dialysis testing lab in the United States. Terms of the acquisition were not disclosed.

After years of struggling with hurdles such as generic competition and significantly lower-than-expected sales of its top meds, Acorda Therapeutics is hanging up the gloves with a $185 million deal to...

Targeting RAS family proteins in FLT3-ITD+ Acute Myeloid Leukemia shuts off a common route to drug resistance. Relapses in a common form of leukemia may be preventable following new research which...

J&J and Legend’s CAR-T cell therapy has been approved as a second-line therapy for patients with multiple myeloma. J&J and Legend Biotech’s Carvykti is a B-cell maturation antigen (BCMA) d...

A new drug application (NDA) from US-Ireland speciality pharmaceutical company Shorla Oncology has been accepted by the US Food and Drug Administration (FDA) for SH-201, an oral versio...

Acumen Pharmaceuticals has entered a strategic partnership with Swiss contract manufacturer Lonza to further the development of sabirnetug (ACU193), a potential treatment for Alzheimer’s dis...

Last month, Amylyx announced that the Phase III confirmatory trial of ALS drug Relyvrio failed to meet its primary and secondary endpoints.

GSK’s Trelegy Ellipta has been approved as a maintenance therapy for both asthma and COPD in Singapore. Trelegy Ellipta is approved as a maintenance treatment for COPD and asthma in the US.